Get the Stockscreener App
4.05
0.75%
0.03
Organogenesis Holdings Inc stock is traded at $4.05, with a volume of 1.15M.
It is up +0.75% in the last 24 hours and up +30.65% over the past month.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.
See More
Previous Close:
$4.02
Open:
$4.08
24h Volume:
1.15M
Relative Volume:
2.25
Market Cap:
$536.93M
Revenue:
$433.14M
Net Income/Loss:
$4.95M
P/E Ratio:
49.63
EPS:
0.0816
Net Cash Flow:
$6.55M
1W Performance:
+4.92%
1M Performance:
+30.65%
6M Performance:
+43.62%
1Y Performance:
+56.37%
1-Day Range:
$4.01
$4.21
1-Week Range:
$3.76
$4.21
52-Week Range:
$2.165
$4.705
Organogenesis Holdings Inc Stock (ORGO) Company Profile
Name
Organogenesis Holdings Inc
Sector
Phone
781-575-0775
Address
85 DAN ROAD, CANTON, MA
Compare ORGO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ORGO | 4.05 | 536.93M | 433.14M | 4.95M | 6.55M | 0.0816 |
| ZTS | 176.96 | 79.84B | 9.15B | 2.43B | 2.31B | 4.92 |
| HLN | 9.65 | 43.63B | 14.26B | 1.55B | 0 | 0.3327 |
| TAK | 13.38 | 42.42B | 30.27B | 1.93B | 3.45B | 0.444 |
| TEVA | 17.12 | 19.40B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.37 | 15.96B | 15.05B | -883.30M | 1.89B | 1.53 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Lake Street | Buy |
| Feb-07-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-23 | Initiated | Morgan Stanley | Equal-Weight |
| May-24-23 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-10-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-19 | Resumed | Credit Suisse | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
| Apr-17-19 | Initiated | Oppenheimer | Outperform |
| Apr-11-19 | Initiated | SunTrust | Buy |
View All
Organogenesis Holdings Inc Stock (ORGO) Latest News
Organogenesis Holdings Inc. Expands Manufacturing Capacity to Support Future Growth - Marketscreener.com
Organogenesis Expands Manufacturing Capacity to Support Future Growth - The Manila Times
Organogenesis Secures 122,000 Sq Ft Biomanufacturing Facility in Major Expansion | ORGO Stock News - StockTitan
Organogenesis Holdings Inc. Appoints Garrett Lustig to the Board - Marketscreener.com
Analysts Set Expectations for Organogenesis FY2024 Earnings - Defense World
FY2024 EPS Estimates for Organogenesis Boosted by Analyst - MarketBeat
Organogenesis Holdings’ $130 Million Private Placement Offering of Series A Convertible Preferred Stock - Global Legal Chronicle
Organogenesis (NASDAQ:ORGO) Releases Quarterly Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat
Organogenesis Commends Final LCDs - The Manila Times
Organogenesis Secures Medicare Coverage for Wound Care Products in Key CMS Decision | ORGO Stock News - StockTitan
Organogenesis (NASDAQ:ORGO) Shares Gap DownWhat's Next? - MarketBeat
Earnings call: Organogenesis tops Q3 revenue forecast with $115.2M - Investing.com
Organogenesis Holdings Secures $130M Investment for Growth - TipRanks
Organogenesis Holdings Inc. (NASDAQ:ORGO) Q3 2024 Earnings Call Transcript - Insider Monkey
Organogenesis secures $130 million investment By Investing.com - Investing.com Australia
Organogenesis: Q3 Earnings Snapshot - The Washington Post
Organogenesis Reports Robust Third Quarter Growth - TipRanks
Organogenesis (ORGO) Q3 2024 Earnings Call Transcript - The Motley Fool
Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates - Yahoo Canada Finance
Organogenesis Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock - The Manila Times
Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results - The Manila Times
Organogenesis Secures $130M Investment from Avista, Strengthens Growth Strategy | ORGO Stock News - StockTitan
ORGOOrganogenesis Holdings Inc. Latest Stock News & Market Updates - StockTitan
Organogenesis Holdings Inc. announced that it expects to receive $130 million in funding from Avista Healthcare Partners - Marketscreener.com
Organogenesis Phase 3 Trial Success: ReNu Knee Treatment Shows Promising Results | ORGO Stock News - StockTitan
Advanced Wound Care Market growing at a CAGR of 5.6% from 2023 - openPR
Organogenesis (ORGO) Set to Announce Earnings on Tuesday - Defense World
$5M grant key to R.I. biotech deal in Smithfield - Providence Business News
Organogenesis Holdings And 2 Other US Penny Stocks To Watch - Simply Wall St
Mass. company offered millions to manufacture artificial skin in the Ocean State - The Business Journals
Business | McKee Administration Poised to Give Major Incentives to Boston Biotech Firm - GoLocalProv
Organogenesis eyes former Rubius site in SmithfieldProvidence Business First - The Business Journals
Mass.-based biotech firm looks to expand to former Rubius facility in Smithfield - Providence Business News
Shareholders in Organogenesis Holdings (NASDAQ:ORGO) are in the red if they invested three years ago - Yahoo Finance
Assenagon Asset Management S.A. Has $5.48 Million Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO) - MarketBeat
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024 - The Manila Times
Market Highlights: Organogenesis Holdings Inc (ORGO) Ends on a High Note at 3.09 - The Dwinnex
Cubist Systematic Strategies LLC Acquires 88,175 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) - Defense World
Organogenesis: Lurking Disruption With Recovery To Follow (NASDAQ:ORGO) - Seeking Alpha
Cantor Fitzgerald Comments on Organogenesis Holdings Inc.'s FY2024 Earnings (NASDAQ:ORGO) - MarketBeat
Amniotic Membrane Market to See Booming Growth 2024-2031 | Smith - openPR
Dimensional Fund Advisors LP Raises Position in Organogenesis Holdings Inc. (NASDAQ:ORGO) - MarketBeat
Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Purchased by AQR Capital Management LLC - Defense World
AQR Capital Management LLC Grows Stock Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO) - MarketBeat
Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers - ForexTV.com
Healthy Upside Potential: Organogenesis Holdings Inc (ORGO) - SETE News
Organogenesis Holdings Inc. (NASDAQ:ORGO) Short Interest Update - MarketBeat
Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Acquired by Massachusetts Financial Services Co. MA - Defense World
Bank of New York Mellon Corp Increases Position in Organogenesis Holdings Inc. (NASDAQ:ORGO) - Defense World
WINTON GROUP Ltd Sells 4,139 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) - Defense World
Organogenesis Holdings Inc Stock (ORGO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.66%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):